Abstract
Thermal burn injury (TBI) is an important source of morbidity and mortality. The exact mechanisms for the systemic effects including multiple organ dysfunction (MOD) and immune deficits associated with extensive skin burn injuries are unclear and this knowledge gap has negatively impacted therapy. The goal of this review is to present evidence for a model of TBI-induced systemic effects that involves skin keratinocyte release of subcellular microvesicle particles (MVP) carrying the potent lipid mediator Platelet-activating Factor (PAF) as effectors. As TBI has been shown to generate high levels of potent 1-alkyl PAF versus lesser amounts of inhibitory 1-acyl PAF species, it would be expected that MVP produced by burn would be highly powerful PAF receptor agonists. In addition, we present results of a pilot study with 12 human subjects suggesting that MVP can be measured systemically within hours following a TBI. This model involving MVP provides an explanation for why advanced age and ethanol intoxication result in worsening systemic effects including MOD following a TBI. The need for more clinical studies in this critical area of TBI pathogenesis is also discussed. Potential therapeutic implications of this model will also be addressed. An improved understanding of how a significant skin burn injury results in systemic manifestations will result in improved TBI patient outcomes and could be applicable to other environmental stressors.
1 Introduction
According to the World Health Organization, burns are defined as cellular and tissue injuries primarily caused by heat, radiation, radioactivity, electricity, and the toxic effects of applied chemicals. These injuries drive approximately 400,000 individuals in the United States every year to seek medical treatment, and worldwide it is estimated that burns cause at least 265,000 mortalities annually (1). These injuries incur over 300,000 US-based inpatient hospitalizations and an estimated 40% of those injuries occur from flames and other thermal processes (2). Thermal burn injuries, or TBI’s, can present an acutely urgent issue with typical treatment sought either within minutes to hours for severe incapacitating burns to within the first two days following lesser injuries. The time before seeking medical attention is crucial to improve the mortality of an individual pending the extent of the burn (3).
The prevalence of burns worldwide exceeds an estimated six million injuries yearly with over 265,000 of those individuals dying from the effects of the burns (1, 4). Care of the severe TBI victim imposes a yearly cost of hundreds of thousands with financial burdens ranging from approximately $270,000 to $361,000 per individual. As a country these costs in the United States amount to over one billion dollars annually (5) with increasingly long hospital stays and increased costs when concomitant inhalation burns and increased body surface areas are affected (6). Contributors to the rising costs of these injuries, including a higher incidence of the injury as well as increasing costs for medical treatment and resources allocated to these patients, have rationalized the presence of multiple dedicated burn centers around the country. These burn centers have resulted in the overall improvement of the both acute and chronic care for the TBI patient (7).
2 Systemic effects of TBI
2.1 Background on TBI systemic effects
Thermal burn injuries, apart from damage to the superficial skin layers, cause systemic pathologies to individuals including but not limited to ischemic necrotic bowel disease (8), acute renal injury (9), bacteremia and associated systemic infectious processes, shock with hypoperfusion of end organs, muscle wasting (10), metabolic consequences, disseminated intravascular coagulation (11) and many more (12). Burns initiate a cascade of cellular processes including coagulation, cytokine induced inflammation, and subsequent tissue granulation at later stages of the pathophysiologic process. These injuries can result in low rates of perfusion following hyperemia, heightened hematologic levels of cellular components from necrotic tissue, and a state of immunosuppression (5).
Following the Jackson model of the burn wound, burns produce three distinct zones related to the damage incurred. The first zone is coagulation where the most tissue damage occurs. Irreversible tissue loss occurs due to the coagulation of abundant proteins within the cellular matrix. The second region is the zone of stasis. In this zone, tissue has decreased perfusion however as a whole can be deemed viable; this zone surrounds the coagulation zone. The third area is the zone of hyperemia. This zone is the most peripheral from the central burn and has the least cellular injury of the three zones. Here also lies the most perfused of the three zones and thus exhibits the highest probability of tissue recovery (13). The actual size of the injury is important as systemic effects occur with higher incidence following an approximately >20% surface area injury (14, 15) As will detail further in this review, systemic effects appear to be in great part due to products of the systemic inflammatory response. The pathologic abnormalities noted following severe TBI include widespread inflammation, increased vascular permeability, inducing disseminated intravascular coagulation, dehydration, hemolysis, and other cellular and tissue death.
2.2 Risk factors for systemic effects
Burn injuries, judged in severity by depth and total body surface area covered, affect all age groups. However, those most predisposed to severe effects from burns include those >60 years or less than <2 years of age (14). Other factors associated with a poorer prognosis from TBI include concurrent trauma and smoke inhalation, immunosuppression, and ethanol intoxication (12, 16, 17). Obesity, an abundant comorbidity faced today within the United States, has been correlated with increased incidences of systemic bacteremia, deep vein thrombosis, pulmonary embolism, and increased hospital stays following burn injuries (18).
Previous studies have demonstrated that those engaging in risky behaviors, such as utilizing inebriating substances like alcohol, exhibit an increased incidence of TBI. Other risk factors for TBI include utilizing electronic cigarettes that have been shown to detonate with use (19). Dangerous professions from firefighting to working around hot surfaces such as furnaces or stoves also have higher incidences of TBI (20).
2.3 Animal models for investigating systemic effects of thermal burn injuries
Animal models have been valuable tools for unravelling the intricate pathways involved in the systemic responses associated with burn injury. In vitro models are currently unable to fully stimulate the complex pathophysiology and clinical features of human burn injuries. Thus, animal models are an indispensable tool for researchers to understand both the post-burn pathophysiology as well as to evaluate innovative therapeutic strategies, enabling research that is ethically infeasible in clinical settings. Primary challenges in burn research with animal models include the lack of an ideal animal model which will replicate all the diverse features of human burn trauma (21). Additionally, it can be difficult to produce uniform burn injuries with consistent depth and characteristics for reliable research (22). Despite these challenges, animal models have played a significant role in elucidating both molecular and cellular characteristics that define human burn injuries (23).
In thermal burn research, rodents (mice and rats), pigs, and rabbits are the most used animal models. Mice are often utilized because of their ease of genetic alteration, cost-effectiveness, quick breeding, and reasonable genetic resemblance to humans (21). Burn inflicted on large animal models like sheep, or swine is also considered sufficient to reproduce many findings including a significant hypermetabolic response (24). Rabbits, although less commonly used for burn research, provide intermediate anatomical similarities in skin structure and thickness, offering additional translational value in specific contexts (25).
Depending on the species and the study issue, different techniques are employed to generate burns in animal models. To simulate the unintentional scald injuries observed in pediatric patients, rat and mice models frequently undergo scald burns, which are created by submerging the skin in hot water (26). With contact burns, consistent partial- or full-thickness burns can be produced by applying hot metal objects at regulated temperatures for predetermined amounts of time (27, 28). In order to investigate the combined consequences of thermal and pulmonary injuries, smoke inhalation models are frequently used in conjunction with flame burns, which simulate fire exposure (21).
2.4 Murine models of TBI and intoxicated TBI
Murine models are not only essential tools for understanding and evaluating the complex systemic pathophysiology of TBI, they have use in testing potential therapeutic interventions (21). Mice are extensively used due to their manageability, cost-effectiveness, and well-characterized immune system, in spite of their inherent anatomical and physiological distinctions from human skin, such as thinner epidermis and dermis, dense hair, and primary healing through wound contraction (21, 29, 30). Anesthesia, shaving the dorsal surface, and immersing a predetermined total body surface area (TBSA) into hot water, often at 95-100°C for 7–10 seconds to create full-thickness scald injuries are standard methods of burn induction in mice (21, 26, 31). Other methodologies which appear to generate similar findings involve use of metal blocks heated to ~90°C applied to murine skin (27, 28). Immediate administration of pain relief medication like buprenorphine and resuscitation fluids, such as saline are some post burn care measures employed (26, 27, 32).
The detrimental impact and outcomes of murine burn injury and similarities to the human condition have been demonstrated by the research conducted by Elizabeth J. Kovacs and Mashkoor Choudhry and colleagues. Their studies consistently demonstrate that acute ethanol exposure prior to thermal injury significantly exacerbates immune suppression and systemic inflammation (26, 33). Significant findings include pronounced T-cell dysfunction and increased production of pro-inflammatory cytokines, especially interleukin-6 (IL-6), which is positively correlated with immunosuppression and increased mortality (32, 34, 35). Furthermore, work from these investigators has detailed how the combined insult severely compromises gut barrier function, leading to increased intestinal permeability and heightened bacterial translocation to mesenteric lymph nodes, thereby contributing to widespread systemic sepsis and resultant end organ damage (36, 37). There are several lines of investigation which have linked the increased gut bacterial translocation with the subsequent multiple organ dysfunction. First, the TBI-induced intestinal permeability has been found to be due to gut intestinal activation of myosin light chain kinase (MLCK), and pharmacologic inhibition of this enzyme blocks the systemic organ inflammation following intoxicated TBI (38). Second, mice deficient in toll like receptor 4 (which recognizes gram negative bacterial products) are protected from burn-induced systemic inflammation (39). Aged mice, already exhibiting impaired immune responses, show even greater susceptibility to infections and increased mortality after burns which is linked to increased bacterial translocation from the gut (32, 40). Collectively, the model that has emerged from groundbreaking murine studies has indicated that TBI has the ability to signal internally. Yet, the exact potential effectors linking the skin and lung burn injury have not been elucidated until recently.
3 Microvesicle particles & platelet-activating factor as mediators for TBI systemic effects
3.1 Microvesicles and platelet-activating factor
Microvesicle particles (MVPs), also called large extracellular vesicles, are membrane-bound vesicles that are discharged from the plasma membrane of different cell types in both healthy and pathological situations. Even though the exact mechanism of MVP release from the plasma membrane is not completely known, the involvement of acid sphingomyelinase (aSMase) in some systems have been identified (41). Microvesicle particles have a diameter of around 100 to 1000 nm whereas smaller exosomes released from inside the cell are ~30–150 nm (42–44). Their involvement in intercellular communication, modulating vital processes in cellular homeostasis, immunological regulation, coagulation, and inflammation, accounts for their biological relevance. It should be noted that the biologic effects of subcellular particles such as MVP are due to their carried contents, to include bioactive agents on the particle surface.
Platelet-activating Factor (PAF; 1-alkyl-2-acetyl glycerophosphocholine) is a potent phospholipid mediator and a family of glycerophosphocholine (GPC)-derived lipid mediators implicated in numerous physiological and pathophysiological processes, including inflammation and apoptosis (45, 46). This novel glycerophosphocholine-based mediator PAF was initially described for its ability to cause platelet aggregation but later recognized as a potent activator of various cell types including monocytes, mast cells and leukocytes. PAF species are generated by both enzymatic processes as well as via ROS-mediated oxidation of membrane glycerophospholipids (47). Intradermal administration of PAF can lead to cutaneous inflammation and is present in various inflammatory skin disorders (48–50). PAF binds to a single G-protein-coupled receptor, the PAF receptor (PAFR) to exerts its biological actions (45). Exogenous PAF given to mice can mimic sepsis (51). Though a highly potent and “dangerous” mediator, PAF is quickly inactivated by acetyl transferases as well as alkaline sphingomyelinase found in cells and serum (52, 53).
As is the case with many powerful bioactive agents such as TNF and IL-1, considerable data suggests that the PAF system also has an endogenous antagonist. Once the structure of PAF was elucidated, it was noted that the 1-alkyl PAF species were at least 100 times more potent than the 1-acyl PAF species that were also generated (50, 54). More recent studies have demonstrated that though both 1-alkyl PAF and 1-acyl PAF attach to the same binding pocket of the PAFR, 1-acyl PAF have a lower dissociation rate. Moreover, 1-acyl PAF binding results in structural instability and does not allow proper G protein signaling (55). Consistent with 1-acyl PAF species serving as an endogenous PAFR antagonist, cellular studies have demonstrated that 1-palmitoyl-2-acetyl-GPC pre-treatment blocks the signaling of subsequent 1-hexadecyl-2-acetyl GPC (50, 56). Providing mice with 1-acyl PAF along with 1-alkyl PAF protects mice from lethal acute effects of the latter (57). Relevant to burn injury, previous studies have demonstrated that HaCaT keratinocytes generate only 1-alkyl PAF in response to an experimental TBI, whereas approximately equal amounts of both species are produced in response to other stimuli such as cold injury or ionophore A23187 (57–59).
3.2 Structural characteristics and composition of MVP
Microvesicle particles come in a variety of shapes, most often ellipsoid or spherical. Their stable and bioactive lipid bilayer is mostly taken from the plasma membrane of the parent cell and is enhanced with cholesterol and phospholipids. Phosphatidylserine, tetraspanins (CD9, CD63, and CD81), integrins, and selectins are examples of common surface indicators that help with interactions with recipient cells (60). Like all subcellular particles, MVP express surface or internal markers that can be used to identify the cell of origin. For example, skin keratinocytes have been reported to express the epithelial-selective marker calcium sensing receptor (61). Thus, MVP effects in a variety of biological processes influenced by their markers as well as varied bioactive cargo, which includes proteins (growth factors, cytokines, proteases), lipids (sphingomyelin, ceramides), nucleic acids (mRNA, miRNA), and enzymatic components such acid sphingomyelinase (aSMase) (62).
Previous burn injury research has been complemented by our own group’s mechanistic murine studies which have focused on lipid PAF receptor signaling and subcellular microvesicle particles. Damage to the keratinocyte by heat or cold injury results in PAF biosynthesis (58). Our studies have also revealed that ethanol significantly augments the enzymatic production of PAF in skin keratinocytes during thermal burn injury through hyper-activation of the PAF-generating enzyme cytosolic phospholipase A2 (27, 59, 63). The PAF generated in response to TBI (with increased amounts in response to intoxicated TBI) then activate PAF receptors which then trigger the translocation of the enzyme acid sphingomyelinase (aSMase) to the plasma membrane which then generates MVP (28, 63–66). As outlined in Figure 1, these MVPs which carry the PAF agonists residing in the plasma membranes released from the skin keratinocyte act as critical mediators of systemic effects. It has been hypothesized that PAF is protected from degradation by travelling in MVPs throughout the body and thus allowing activation of PAF receptors in the gut, which in turn increases intestinal permeability and leads to bacterial translocation (27, 67). Additionally, PAF-laden MVP could also interact with the mast cell PAFR which will generate immunosuppression (65, 68), a known effect of TBI (26). Consistent with this hypothetical pathway, mice deficient in PAFR or aSMase lack increased systemic MVP, bacterial translocation and the increased multi-organ inflammation and systemic immunosuppression in response to intoxicated TBI (27, 28). This molecular mechanism provides a plausible explanation for the heightened systemic inflammation and gut barrier dysfunction and systemic immunosuppression observed in previously reported burn models. Collectively, these murine intoxicated TBI models not only clarify clinical observations of poorer outcomes in intoxicated burn patients but also identify MVPs as promising potential biomarkers and therapeutic targets, as evidenced by the attenuation of inflammation and systemic immunosuppression with a topical aSMase inhibitor applied immediately post-burn (27, 28).
Figure 1
In addition to MVP carrying PAF agonists, other potential carried bioactive agents have been associated with burn-derived MVP. In particular, the damage-associated High-Motility Group Box-1 (HMGB1) protein has also been found in TBI-derived MVP (69). Of importance, HMGB1-IL-1β complexes identified in the plasma from both murine and human TBI were found to be bioactive as they generated multiple proinflammatory cytokines (e.g., IL-6, IFN-γ) when added to a monocyte cell line (69).
3.3 Mechanisms of MVP release from skin
A variety of events, such as oxidative stress, heat damage, inflammatory cytokines, and physical trauma, cause skin cells to release MVP (67). In vitro studies have documented that MVPs can carry PAF and in a physiologically protective vesicular form in response to TBI (63, 70, 71). Enzymatic PAF synthesis can be triggered by a range of stimuli, including ultraviolet B radiation (UVB), thermal, and cold injury (57, 58, 70). MVP biogenesis is significantly increased by thermal burn damage, particularly when it is coupled with acute ethanol intoxication (intoxicated TBI, or ITBI). The generation and release of MVP in response to multiple stressors can involve PAFR signaling (67).
In this model, TBI induce MVP release and cause both systemic immunosuppression and damage to multiple systemic organs via complex molecular pathways involving activation of aSMase, the myosin light-chain kinase (MLCK) pathway, and PAF signaling (71). Detailed in Figure 1, PAF production is triggered when thermal stress activates cytosolic phospholipase A2 (cPLA2) (27, 59). The enzyme aSMase is activated when PAF binds to the PAFR on keratinocytes, which sets off downstream signaling through mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) (61). The PAF-PAFR axis is essential because, in both cellular keratinocyte and murine models, pharmacologic suppression of cytoplasmic phospholipase A2 (cPLA2) or PAFR or genetic KO of the PAFR prevents MVP release (27, 61, 63). Ceramide produced by aSMase activation encourages membrane curvature and budding, which appear to be essential for MVP production and release (61). Systemic immunosuppression would be triggered when MVPs transport PAF to mast cells, activating PAFR and encouraging mast cell migration to lymph nodes where they increase regulatory T cells as well as immunosuppressive cytokines including IL-10 and TGF-β (28, 61, 65, 68). PAF-enriched MVP attach themselves to the intestinal epithelium PAFR, causing actomyosin contraction, MLCK activation, increased gut permeability and epithelial permeability. This permits bacteria and endotoxin to translocate into the host, resulting in coagulation activation, endotoxemia, inflammatory cytokine storms, and MOD (27).
As previous research has shown, the mortality rate within the elderly population is much higher following extensive thermal burn injuries, citing complications from the weakened immune response that can be mounted (72). Studies with animal models has recently shown that cutaneous burns in aged animals induce increased gut permeability, further causing infiltration of microbiome bacteria and toxins in comparison to young mice (40). We propose that PAF traveling via MVP released from the burn site could also serve as the effectors in the geriatric population.
3.4 Influence of ethanol and aging on TBI outcomes
The presence of ethanol in the blood of burned victims, as previously demonstrated in animal models, exacerbates the MVP release from burn injuries leading to diminished immune responses and increased gut permeability. In humans, burn victims who have concomitant ethanol intoxication have poorer outcomes (15, 34, 73, 74). The pathology in humans appears to mimic the murine model systems with increased cytokine and neutrophil activation systemically, resulting in end organ damage being more dramatic as compared to non-ethanol exposed subjects. In our proposed model (Figure 1), increased enzymatic PAF generation by the combination of ethanol and TBI would explain the increased pathologies.
Older people are more vulnerable to TBI systemic effects due to senescent immunological changes, which include altered cellular signaling pathways, reduced innate and adaptive immune responses, and chronic inflammation (inflammaging) (75). Thinner epidermis and dermis, decreased vascularity, decreased keratinocyte turnover, and compromised barrier integrity are all signs of morphological and functional degeneration in aged skin, which makes deeper burns and slower healing more likely (76, 77).
Comorbid disorders including cardiovascular disease, diabetes, and overall increased frailty are common in elderly burn patients, which reduces resilience and makes resuscitation, wound care, and rehabilitation more difficult. Elderly burn patients are more susceptible to sepsis and MOD, both major contributors to post-burn mortality (74). The amplified systemic inflammatory response, combined with impaired immune resolution mechanisms, promotes systemic cytokine release and vascular dysfunction (40).
3.5 Evidence that TBI generates systemic MVP in humans
Though both in vitro cellular and ex vivo human skin and preclinical in vivo murine studies have demonstrated that TBI is a potent stimulus for MVP release (27, 70), it is unknown whether humans suffering an acute TBI generate systemic MVP. To that end, we initiated pilot studies in which patients who were admitted to the Premier Medical Center Burn Unit (Dayton, Ohio, USA) within 12 hours of a thermal burn injury were enrolled. These studies involving volunteer adult humans were approved by the Wright State University Institutional Review Board, Dayton Ohio (IRB-2023-422) and followed the Declaration of Helsinki Principles. In these studies, following informed consent, 10 mL of whole blood (collected in heparinized tubes) was obtained from the subject at admission to the Burn Unit and a second 10 mL sample obtained at convalescence (24–116 days later). Blood was spun to separate plasma and the plasma underwent differential centrifugation as per our previously published methodologies (61, 70) to obtain MVP and smaller exosomes (small extracellular vesicles). As shown in Figure 2, 12 subjects were tested (4 females; 8 males, aged 23-64; estimated body surface areas ranging from approximately 3-50%) which revealed statistically significant elevated levels of MVPs in the initial sample taken around the time of the initial TBI (within 12 hours) in comparison to the convalescent values. Of interest, the levels of exosomes in this population were unchanged (Figure 2B) suggesting that the elevated MVP levels at the initial sampling was likely not due to concentration differences attributable to changes in fluid status. Though these exploratory pilot studies have significant limitations including small sample size (n = 12) and clinical heterogeneity, they do provide some support for a possible role of MVP in acute human TBI. Importantly, the continuation and expansion of studies such as this should allow this hypothesis to be tested in humans.
Figure 2
4 Current management of TBI systemic effects
4.1 Acute care
Acutely, systemic effects of thermal burn injuries are met with the ABCs of emergency medicine, circulation, airway and breathing. This primary survey occurs prior to more invasive maintenance measures. To address the most immediate complications of hypovolemia and hypothermia, intravenous fluids are provided to prevent and treat shock or the diminished perfusion and oxygen delivery to end-organs. Monitoring urine output as well as other end points of resuscitation are helpful gauges to determine resuscitation status. Wound care, antimicrobials, and fighting oxidative stress through electrolyte supplementation are also current measures often utilized (78).
Systemically, inhalation injuries, extensive TBSA burns, and patients with pre-existing comorbidities that impede healing, or impede circulation will need more intensive care. A Baux score can be calculated which can determine the risk of death as a complication, and other predictive measures can be utilized to determine blanket mortality risk, duration of hospital stay, or the necessity for ICU intervention (16, 79).
4.2 Chronic care
Preventing dehydration, pain medications, creams and ointments to keep the burn sites moist, antibiotics for infections are all acceptable treatment strategies. Chronically, burn injuries take an extensive amount of time to heal and patients must be diligent in management to regain their original function. Physical therapy, pharmacological pain treatment, and outpatient management with diligent wound care is a common regimen pursued. Long-term management of TBI often involves a multi-disciplinary approach including psychological rehabilitation and coping with the offending trauma, establishing a dietary caloric minimum to compensate for the hypermetabolic state and recovery, as well as regular follow-up with wound care professionals for burn management and to avoid complications including skin contractures, sepsis, keloid formation, and chronic hypermetabolism. Additionally, care to manage the long-term sequelae of the MOD including but not limited to renal, hepatic, cardiac, pulmonary, neurologic, and gastrointestinal failure is needed.
4.3 Need for improved management
Though management of the burn victim has been improved via specialized care in dedicated burn centers (7), the standard acute treatments have not changed appreciably in the last several decades. Thus, there is a compelling need for further research in TBI. An improved understanding of the acute TBI pathophysiology should result in new pharmacologic targets to address the potentially lethal MOD as well as the increased susceptibility to infections associated with the acquired immune deficits in the setting of barrier disruption.
4.4 Therapeutic implications & future research opportunities
Acute MOD as discussed is a critical and mortality predicting complication of TBI that is currently managed through ICU level fluid resuscitation and hemodynamic monitoring. However, there is no evidence that fluid monitoring and replacement alone could interrupt the enzymatic cascades resulting in the release of MVPs.
Therapeutic interventions that have recently been explored in animal models to combat MOD and further complications from TBI include MLCK inhibitors (38) and anti-IL-6 antibodies (38). Based upon our model, there is premise for the testing of FIASMs (functional inhibitors of acid-sphingomyelinase) to control MVP release as well as regulate cell signaling (80). Beyond the aSMases and their role within the ceramide cascade that is being researched regarding viral cell signaling (81), this enzyme as previously discussed plays an essential role in the release of MVPs containing PAF following TBI. Utilizing FIASMs including tricyclic antidepressants such as amitriptyline and imipramine which have been shown in prior animal models to inhibit the MVP release following TBI could be repurposed for human studies (27, 28). We have recently demonstrated that topical treatment with imipramine immediately following localized UVB irradiation blocks MVP release in skin (82). An advantage of this approach targeting aSMase is that it could also potentially inhibit the formation of the release of other putative bioactive MVP-carried agents such as HMGB1-IL-1β complexes (69). Further research in this realm is needed to assess efficacy of these relatively safe agents in acute human burn patients.
Other avenues to be explored regarding this area of research include the targeting of multiple enzymatic components of the established cascade, such as the addition of an MLCK inhibitor, FIASM, and/or introducing a “triple therapy” that also involves inhibition of PAF receptors. At present there is only one PAFR antagonist (rupatadine) which is commercially available (83). It should be noted that the vast majority of PAFR antagonists are far less potent than the native 1-alkyl PAF ligand (84). These therapeutic tools in humans may provide evidence for this pathway involving PAF-laden MVPs as well as could potentially revolutionize initial management of the acute TBI patient.
Finally, more clinically-oriented studies similar to the pilot studies presented in this manuscript should be initiated. Data from large numbers of acute TBI patients will allow comparisons of MVP levels with clinical parameters that are known to result in worse outcomes to include age, % body surface area of burn, and presence of ethanol intoxication.
5 Conclusions
The PAFR-aSMase-MVP axis could potentially serve as a critical mechanism which could provide an explanation for how localized cutaneous damage can escalate into severe systemic pathologies. Compelling data from murine studies provide support for MVP involvement in acute TBI-related pathologies. The exploratory human studies presented in this manuscript also fit with the notion that burn-derived MVP could serve as important contributors to the pathologies associated with severe TBI. An improved understanding of the role that MVPs that carry PAF and potentially other mediators play in mediating systemic reactions to burns, such as vascular dysfunction, immunological dysregulation, and increased gut permeability, is crucial. The present-day treatments mainly comprise wound care, infection control, and fluid resuscitation as supportive treatments that do not directly address the upstream signaling cascades which eventually translate into systemic toxicity. Future pharmaceutical approaches may provide novel means for prophylaxis or reduction of systemic complications by targeting molecular mediators such as PAF and aSMase-dependent MVP release identified to play roles in pathophysiology. The success of pharmacological aSMase inhibitors, for example imipramine, in attenuating ITBI-induced systemic inflammation and MVP release in mice, underscore the immense therapeutic potential of targeting this pathway. This research could change how acute TBI is managed, aiming at the molecular mechanisms of the disease to decrease mortality and improve long-term outcomes.
Statements
Author contributions
AP: Investigation, Visualization, Writing – original draft, Conceptualization, Formal analysis. RF: Conceptualization, Investigation, Visualization, Data curation, Writing – original draft. AU: Methodology, Formal analysis, Investigation, Data curation, Writing – review & editing. YP: Methodology, Visualization, Data curation, Validation, Investigation, Writing – review & editing. RJ: Project administration, Visualization, Resources, Supervision, Writing – review & editing. WZ: Writing – review & editing, Investigation, Data curation, Validation. ZX: Writing – review & editing, Formal analysis, Visualization, Supervision. AS: Writing – review & editing, Visualization, Conceptualization, Investigation. CR: Funding acquisition, Investigation, Visualization, Validation, Conceptualization, Writing – review & editing, Supervision. JT: Methodology, Data curation, Writing – original draft, Conceptualization, Investigation, Supervision, Funding acquisition, Writing – review & editing, Project administration.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This research was supported in part by grants from the National Institutes of Health (R01 HL062996 (JT), R01 ES031087 (JT), R34 AR081443 (JT) and Office of Research and Development, U.S. Veterans Administration Merit Awards 5I01BX000853 (JT) and 1101CX002927 (CR, JT).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
SmolleCCambiaso-DanielJForbesAAWurzerPHundeshagenGBranskiLKet al. Recent trends in burn epidemiology worldwide: A systematic review. Burns. (2017) 43:249–57. doi: 10.1016/j.burns.2016.08.013
2
IvankoAGarbuzovAESchoenJEKearnsRPhillipsBMurataEet al. The Burden of Burns: An Analysis of Public Health Measures. J Burn Care Res. (2024) 45(5):1095-1097. doi: 10.1093/jbcr/irae053
3
NemerJAJuarezMA. Thermal burns. In: PapadakisMARabowMWMcQuaidKRGandhiM, editors. Current Medical Diagnosis & Treatment 2025. McGraw-Hill Education, New York, NY (2025).
4
WalkerNJKingKC. Acute and Chronic Thermal Burn Evaluation and Management. Treasure Island (FL: StatPearls (2025).
5
NielsonCBDuethmanNCHowardJMMoncureMWoodJG. Burns: pathophysiology of systemic complications and current management. J Burn Care Res. (2017) 38:e469–e81. doi: 10.1097/BCR.0000000000000355
6
TaylorSLSenSGreenhalghDGLawlessMCurriTPalmieriTL. A competing risk analysis for hospital length of stay in patients with burns. JAMA Surg. (2015) 150:450–6. doi: 10.1001/jamasurg.2014.3490
7
MasonSANathensABByrneJPFowlerRAKaranicolasPJMoineddinRet al. Burn center care reduces acute health care utilization after discharge: A population-based analysis of 1,895 survivors of major burn injury. Surgery. (2017) 162:891–900. doi: 10.1016/j.surg.2017.05.018
8
Kowal-VernAMcGillVGamelliRL. Ischemic necrotic bowel disease in thermal injury. Arch Surg. (1997) 132:440–3. doi: 10.1001/archsurg.1997.01430280114020
9
SabryAEl-DinABEl-HadidyAMHassanM. Markers of tubular and glomerular injury in predicting acute renal injury outcome in thermal burn patients: a prospective study. Ren Fail. (2009) 31:457–63. doi: 10.1080/08860220902963616
10
PorterCHerndonDNSidossisLSBørsheimE. The impact of severe burns on skeletal muscle mitochondrial function. Burns. (2013) 39:1039–47. doi: 10.1016/j.burns.2013.03.018
11
LippiGIppolitoLCervellinG. Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost. (2010) 36:429–36. doi: 10.1055/s-0030-1254051
12
SaffleJRSullivanJJTuohigGMLarsonCM. Multiple organ failure in patients with thermal injury. Crit Care Med. (1993) 21:1673–83. doi: 10.1097/00003246-199311000-00016
13
HettiaratchySDziewulskiP. ABC of burns: pathophysiology and types of burns. Bmj. (2004) 328:1427–9. doi: 10.1136/bmj.328.7453.1427
14
MooreECPilcherDVBaileyMJStephensHClelandH. The Burns Evaluation and Mortality Study (BEAMS): predicting deaths in Australian and New Zealand burn patients admitted to intensive care with burns. J Trauma Acute Care Surg. (2013) 75:298–303. doi: 10.1097/TA.0b013e318295409d
15
StewartBTHunterMAJohnsonLJasonDArbabiS. Initial management of patients with burns and combined injuries for acute care surgeons: What you need to know. J Trauma Acute Care Surg. (2025) 99:10–23. doi: 10.1097/TA.0000000000004559
16
SilverGMAlbrightJMSchermerCRHalerzMConradPAckermanPDet al. Adverse clinical outcomes associated with elevated blood alcohol levels at the time of burn injury. J Burn Care Res. (2008) 29:784–9. doi: 10.1097/BCR.0b013e31818481bc
17
OslerTGlanceLGHosmerDW. Simplified estimates of the probability of death after burn injuries: extending and updating the baux score. J Trauma. (2010) 68:690–7. doi: 10.1097/TA.0b013e3181c453b3
18
RayJJSatahooSSMeizosoJPAllenCJTeischLFProctorKGet al. Does obesity affect outcomes of adult burn patients? J Surg Res. (2015) 198:450–5. doi: 10.1016/j.jss.2015.03.049
19
HickeySGovermanJFriedstatJSheridanRSchulzJ. Thermal injuries from exploding electronic cigarettes. Burns. (2018) 44:1294–301. doi: 10.1016/j.burns.2018.02.008
20
Ortiz-PradoEArmijosLIturraldeAL. A population-based study of the epidemiology of acute adult burns in Ecuador from 2005 to 2014. Burns. (2015) 41:582–9. doi: 10.1016/j.burns.2014.08.012
21
AbdullahiAAmini-NikSJeschkeMG. Animal models in burn research. Cell Mol Life Sci. (2014) 71:3241–55. doi: 10.1007/s00018-014-1612-5
22
ShuklaSKSharmaAKShawPKaloniaAYashavarddhanMHSinghS. Creation of rapid and reproducible burn in animal model with a newly developed burn device. Burns. (2020) 46:1142–9. doi: 10.1016/j.burns.2019.12.005
23
HaoDNourbakhshM. Recent advances in experimental burn models. Biol (Basel). (2021) 10:526. doi: 10.3390/biology10060526
24
AijazAVinaikRJeschkeMG. Chapter 10 - Large animal models of thermal injury. In: MontroseDC, editor. Methods in Cell Biology, vol. 168. Elsevier (2022). p. 191–219. doi: 10.1016/bs.mcb.2021.12.014
25
HuRHYuYMCostaDYoungVRRyanCMBurkeJFet al. A rabbit model for metabolic studies after burn injury. J Surg Res. (1998) 75:153–60. doi: 10.1006/jsre.1998.5274
26
FaunceDEGregoryMSKovacsEJ. Effects of acute ethanol exposure on cellular immune responses in a murine model of thermal injury. J Leukoc Biol. (1997) 62:733–40. doi: 10.1002/jlb.62.6.733
27
LohadeRPBrewerCRappCMHenkelsKMZhangWThyagarajanAet al. Evidence that keratinocyte microvesicle particles carrying platelet-activating factor mediate the widespread multiorgan damage associated with intoxicated thermal burn injury. J Leukoc Biol. (2024) 116:766–78. doi: 10.1093/jleuko/qiae078
28
LohadeRPRappCMHenkelsKMTraversJB. Intoxicated thermal burn injury-mediated systemic immunosuppression involves platelet-activating factor and microvesicle particles. Skin Res Technol. (2024) 30:e13743. doi: 10.1111/srt.13743
29
DahiyaP. Burns as a model of SIRS. Front Biosci (Landmark Ed). (2009) 14:4962–7. doi: 10.2741/3580
30
LateefZStuartGJonesNMercerAFlemingSWiseL. The cutaneous inflammatory response to thermal burn injury in a murine model. Int J Mol Sci. (2019) 20(3):538. doi: 10.3390/ijms20030538
31
MuroIQualmanACMeza MongeKPratapAKovacsEJIdrovoJP. Delayed hepatic response and impaired cytokine dynamics in aged mice following burn injury: Implications for elderly patient care. PLoS One. (2025) 20:e0316813. doi: 10.1371/journal.pone.0316813
32
KovacsEJGrabowskiKADuffnerLAPlackettTPGregoryMS. Survival and cell mediated immunity after burn injury in aged mice. J Am Aging Assoc. (2002) 25:3–9. doi: 10.1007/s11357-002-0001-4
33
ChoudhryMAMessinghamKANamakSColantoniAFontanillaCVDuffnerLAet al. Ethanol exacerbates T cell dysfunction after thermal injury. Alcohol. (2000) 21:239–43. doi: 10.1016/S0741-8329(00)00093-8
34
ChoudhryMAChaudryIH. Alcohol, burn injury, and the intestine. J Emerg Trauma Shock. (2008) 1:81–7. doi: 10.4103/0974-2700.43187
35
PalmerJLDeburghgraeveCRBirdMDHauer-JensenMKovacsEJ. Development of a combined radiation and burn injury model. J Burn Care Res. (2011) 32:317–23. doi: 10.1097/BCR.0b013e31820aafa9
36
ZahsABirdMDRamirezLChoudhryMAKovacsEJ. Anti-IL-6 antibody treatment but not IL-6 knockout improves intestinal barrier function and reduces inflammation after binge ethanol exposure and burn injury. Shock. (2013) 39:373–9. doi: 10.1097/SHK.0b013e318289d6c6
37
ChenMMZahsABrownMMRamirezLTurnerJRChoudhryMAet al. An alteration of the gut-liver axis drives pulmonary inflammation after intoxication and burn injury in mice. Am J Physiol Gastrointest Liver Physiol. (2014) 307:G711–8. doi: 10.1152/ajpgi.00185.2014
38
ZahsABirdMDRamirezLTurnerJRChoudhryMAKovacsEJ. Inhibition of long myosin light-chain kinase activation alleviates intestinal damage after binge ethanol exposure and burn injury. Am J Physiol Gastrointest Liver Physiol. (2012) 303:G705–12. doi: 10.1152/ajpgi.00157.2012
39
BirdMDZahsADeburghgraeveCRamirezLChoudhryMAKovacsEJ. Decreased pulmonary inflammation following ethanol and burn injury in mice deficient in TLR4 but not TLR2 signaling. Alcohol Clin Exp Res. (2010) 34:1733–41. doi: 10.1111/j.1530-0277.2010.01260.x
40
NajarroKMBoeDMWalrathTMMullenJEPaulMTFrankelJHet al. Advanced age exacerbates intestinal epithelial permeability after burn injury in mice. Exp Gerontol. (2022) 158:111654. doi: 10.1016/j.exger.2021.111654
41
BiancoFPerrottaCNovellinoLFrancoliniMRigantiLMennaEet al. Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J. (2009) 28:1043–54. doi: 10.1038/emboj.2009.45
42
AnandSSamuelMKumarSMathivananS. Ticket to a bubble ride: Cargo sorting into exosomes and extracellular vesicles. Biochim Biophys Acta Proteins Proteom. (2019) 1867:140203. doi: 10.1016/j.bbapap.2019.02.005
43
AntonyakMALiBBoroughsLKJohnsonJLDrusoJEBryantKLet al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A. (2011) 108:4852–7. doi: 10.1073/pnas.1017667108
44
DeanJNiedereggerTHochCCMahetaBWollenbergBMroskFet al. Extracellular vesicles in head and neck cancer: mediators of oncogenesis, immune evasion, and therapy resistance. Front Immunol. (2025) 16:1642639. doi: 10.3389/fimmu.2025.1642639
45
ShimizuT. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. (2009) 49:123–50. doi: 10.1146/annurev.pharmtox.011008.145616
46
TraversJBRohanJGSahuRP. New insights into the pathologic roles of the platelet-activating factor system. Front Endocrinol (Lausanne). (2021) 12:624132. doi: 10.3389/fendo.2021.624132
47
KongerRLMaratheGKYaoYZhangQTraversJB. Oxidized glycerophosphocholines as biologically active mediators for ultraviolet radiation-mediated effects. Prostaglandins Other Lipid Mediat. (2008) 87:1–8. doi: 10.1016/j.prostaglandins.2008.04.002
48
GrandelKEFarrRSWandererAAEisenstadtTCWassermanSI. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med. (1985) 313:405–9. doi: 10.1056/NEJM198508153130702
49
GuinotPBraquetPDuchierJCournotA. Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF antagonist. Prostaglandins. (1986) 32:160–3. doi: 10.1016/0090-6980(86)90161-9
50
TraversJBMurphyRCJohnsonCAPeiYMorinSMClayKLet al. Identification and pharmacological characterization of platelet-activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. Prostaglandins Other Lipid Mediat. (1998) 56:305–24. doi: 10.1016/S0090-6980(98)00060-4
51
AbhilashaKVSumanthMSChaithraVHJacobSPThyagarajanASahuRPet al. p38 MAP-kinase inhibitor protects against platelet-activating factor-induced death in mice. Free Radic Biol Med. (2019) 143:275–87. doi: 10.1016/j.freeradbiomed.2019.08.019
52
WuJNilssonAJönssonBAStenstadHAgaceWChengYet al. Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity. Biochem J. (2006) 394:299–308. doi: 10.1042/BJ20051121
53
KonoNAraiH. Platelet-activating factor acetylhydrolases: An overview and update. Biochim Biophys Acta Mol Cell Biol Lipids. (2019) 1864:922–31. doi: 10.1016/j.bbalip.2018.07.006
54
SnyderF. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. (1990) 259:C697–708. doi: 10.1152/ajpcell.1990.259.5.C697
55
HungSCChenCCChanHCChanMLNguiYSMeiJBet al. Structural and molecular dynamics insights into the competitive inhibition of the platelet-activating factor receptor by acyl-PAF. J Biol Chem. (2025) 301:110831. doi: 10.1016/j.jbc.2025.110831
56
ChaithraVHJacobSPLakshmikanthCLSumanthMSAbhilashaKVChenCHet al. Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF. J Lipid Res. (2018) 59:2063–74. doi: 10.1194/jlr.M085704
57
TraversJBHarrisonKAJohnsonCAClayKLMorelliJG. Platelet-activating factor biosynthesis induced by various stimuli in human HaCaT keratinocytes. J Invest Dermatol. (1996) 107:88–94. doi: 10.1111/1523-1747.ep12298295
58
AlappattCJohnsonCAClayKLTraversJB. Acute keratinocyte damage stimulates platelet-activating factor production. Arch Dermatol Res. (2000) 292:256–9. doi: 10.1007/s004030050483
59
HarrisonKARomerEWeyerbacherJOcanaJASahuRPMurphyRCet al. Enhanced platelet-activating factor synthesis facilitates acute and delayed effects of ethanol-intoxicated thermal burn injury. J Invest Dermatol. (2018) 138:2461–9. doi: 10.1016/j.jid.2018.04.039
60
ColomboMRaposoGThéryC. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. (2014) 30:255–89. doi: 10.1146/annurev-cellbio-101512-122326
61
LiuLAwoyemiAAFahyKEThapaPBorchersCWuBYet al. Keratinocyte-derived microvesicle particles mediate ultraviolet B radiation-induced systemic immunosuppression. J Clin Invest. (2021) 131(10):e144963. doi: 10.1172/JCI144963
62
van NielGD’AngeloGRaposoG. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. (2018) 19:213–28. doi: 10.1038/nrm.2017.125
63
AwoyemiAABorchersCLiuLChenYRappCMBrewerCAet al. Acute ethanol exposure stimulates microvesicle particle generation in keratinocytes. Toxicol Lett. (2022) 355:100–5. doi: 10.1016/j.toxlet.2021.11.008
64
JiangTSamapatiRKlassenSWinoto-MorbachSMohamedZHGöggelRet al. Mannose-6-phosphate attenuates acute lung injury by competitive release of acid sphingomyelinase from the mannose-6-phosphate receptor in endothelial caveolae. Eur Respir J. (2025) 65:2400003. doi: 10.1183/13993003.00003-2024
65
OcanaJARomerESahuRPawelzikSCFitzGeraldGAKaplanMHet al. Platelet-activating factor-induced reduction in contact hypersensitivity responses is mediated by mast cells via cyclooxygenase-2-dependent mechanisms. J Immunol. (2018) 200:4004–11. doi: 10.4049/jimmunol.1701145
66
GöggelRWinoto-MorbachSVielhaberGImaiYLindnerKBradeLet al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med. (2004) 10:155–60. doi: 10.1038/nm977
67
ParkYSahuRPRohanCAKempMGThyagarajanATraversJB. Evidence for keratinocyte-derived microvesicle particles as carriers for the potent lipid mediator platelet-activating factor as effectors for systemic effects associated with many environmental stressors. J Invest Dermatol. (2025) S0022-202X(25)03554-7. doi: 10.1016/j.jid.2025.10.614
68
BernardJJGalloRLKrutmannJ. Photoimmunology: how ultraviolet radiation affects the immune system. Nat Rev Immunol. (2019) 19:688–701. doi: 10.1038/s41577-019-0185-9
69
ColemanLGJr.MaileRJonesSWCairnsBACrewsFT. HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses to burn injury. PLoS One. (2018) 13:e0195335. doi: 10.1371/journal.pone.0195335
70
LiuLFahyKEAwoyemiAAThapaPKellyLEChenJet al. Thermal burn injury generates bioactive microvesicles: evidence for a novel transport mechanism for the lipid mediator platelet-activating factor (PAF) that involves subcellular particles and the PAF receptor. J Immunol. (2020) 205:193–201. doi: 10.4049/jimmunol.1901393
71
RohanCJLohadeRPBrewerCTraversJB. Platelet-activating factor and microvesicle particles as potential mediators for the toxicity associated with intoxicated thermal burn injury. Biofactors. (2022) 48:1250–6. doi: 10.1002/biof.1917
72
McMahanRHBoeDMWalrathTMIdrovoJPKovacsEJ. Aging, cutaneous burn injury and multi-organ complications: the role of the gut. Adv Geriatr Med Res. (2022) 4(2):e220004. doi: 10.20900/agmr20220004
73
ThalERBostROAndersonRJ. Effects of alcohol and other drugs on traumatized patients. Arch Surg. (1985) 120:708–12. doi: 10.1001/archsurg.1985.01390300058010
74
CroweCSMassenburgBBMorrisonSDNaghaviMPhamTNGibranNS. Trends of burn injury in the United States: 1990 to 2016. Ann Surg. (2019) 270:944–53. doi: 10.1097/SLA.0000000000003447
75
RaniMSchwachaMG. Aging and the pathogenic response to burn. Aging Dis. (2012) 3:171–80.
76
RomanowskiKSSenS. Wound healing in older adults with severe burns: Clinical treatment considerations and challenges. Burns Open. (2022) 6:57–64. doi: 10.1016/j.burnso.2022.01.002
77
EllosoMKambliAAijazAvan de KampAJeschkeMG. Burns in the elderly: potential role of stem cells. Int J Mol Sci. (2020) 21(13):4604. doi: 10.3390/ijms21134604
78
VivóCGaleirasRdel CazMD. Initial evaluation and management of the critical burn patient. Med Intensiva. (2016) 40:49–59. doi: 10.1016/j.medin.2015.11.010
79
MooreECPilcherDVBaileyMJClelandHMcNameeJ. A simple tool for mortality prediction in burns patients: APACHE III score and FTSA. Burns. (2010) 36:1086–91. doi: 10.1016/j.burns.2010.03.013
80
KornhuberJTripalPReichelMTerflothLBleichSWiltfangJet al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem. (2008) 51:219–37. doi: 10.1021/jm070524a
81
PaulettoPJTDelgadoCPda RochaJBT. Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2. Cell Biochem Funct. (2023) 41:284–95. doi: 10.1002/cbf.3789
82
AnnamrajuROwensMSThyagarajanACorbinDASherwinCMTBryantJet al. Possible involvement of keratinocyte-derived microvesicle particles in human photosensitivity disorders. Photochem Photobiol. (2025). doi: 10.1111/php.70058
83
MerlosMGiralMBalsaDFerrandoRQueraltMPuigdemontAet al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. (1997) 280:114–21. doi: 10.1016/S0022-3565(24)36413-4
84
SaundersRNHandleyDA. Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol. (1987) 27:237–55. doi: 10.1146/annurev.pa.27.040187.001321
Summary
Keywords
alcohol, microvesicles, multiple organ dysfunction, platelet-activating factor, thermal burn injury
Citation
Parackal AV, Fox RC, Umerani A, Park Y, Johnson RM, Zhang W, Xu Z, Smith AA, Rohan CA and Travers JB (2026) Evidence for microvesicle particles and platelet-activating factor as effectors for systemic effects of thermal burn injury. Front. Immunol. 17:1771102. doi: 10.3389/fimmu.2026.1771102
Received
18 December 2025
Revised
02 February 2026
Accepted
02 February 2026
Published
24 February 2026
Volume
17 - 2026
Edited by
Frederik Denorme, University of Antwerp, Belgium
Reviewed by
Blair Zachary Johnson, University of Western Australia, Australia
Fatemeh Mohammadyari, Gilan University of Medical Sciences, Iran
Updates
Copyright
© 2026 Parackal, Fox, Umerani, Park, Johnson, Zhang, Xu, Smith, Rohan and Travers.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jeffrey B. Travers, jeffrey.travers@wright.edu
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.